N1-[1-[3-aryl-1-(pyridin-2-, 3-, and 4-yl)-3-oxo] propyl]-2-pyridinecarboxamidrazone derivatives were synthesized and tested for their in vitro antimycobacterial activity. Some compounds showed interesting activity against a strain of Mycobacterium tuberculosis and a strain of Mycobacterium avium.